Design and validation of small interfering RNA on respiratory syncytial virus M2-2 gene: A potential approach in RNA interference on viral replication

Journal of Virological Methods

Volumn 236, Issue , 2016, Pages 117-125

  Chin, V K ^a   Atika Aziz, Nur A ^a   Hudu, Shuaibu A ^a,b   Harmal, Nabil S ^c   Syahrilnizam, A ^a   Jalilian, Farid A ^d   Zamberi, S ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b USMANU DANFODIYO UNIVERSITY   (Nigeria)

^c SANA A UNIVERSITY   (Yemen)

^d ILAM UNIVERSITY   (Iran)

Author keywords

Antiviral; Gene silencing; Respiratory syncytial virus; RNA interference; Small interfering RNA

Indexed keywords

GREEN FLUORESCENT PROTEIN; M2 2 PROTEIN; MESSENGER RNA; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; HYBRID PROTEIN; M2-2 PROTEIN, RESPIRATORY SYNCYTIAL VIRUS; VIRAL PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE CONSTRUCT; GENE SILENCING; GENE TARGETING; GENETIC ALGORITHM; GENETIC TRANSFECTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IN VITRO STUDY; INFECTION; M2 2 GENE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECOMBINANT PLASMID; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VALIDATION PROCESS; VERO CELL LINE; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; WEB BROWSER; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; FLUOROMETRY; GENETICS; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; FLOW CYTOMETRY; FLUOROMETRY; GREEN FLUORESCENT PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84979266696     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2016.07.012     Document Type: Article

References (36)

1. Abernathy, E., Glaunsinger, B., Emerging roles for RNA degradation in viral replication and antiviral defense. Virol. J. 479 (2015), 600–608.
2. Aigner, A., Cellular delivery in vivo of siRNA-based therapeutics. Curr. Pharm. Des. 14:34 (2008), 3603–3619.
3. Alvarez, R., Elbashir, S., Borland, T., Toudjarska, I., Hadwiger, P., John, M., Roehl, I., Morskaya, S.S., Martinello, R., Kahn, J., RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents. Chemother. 53:9 (2009), 3952–3962.
4. Bermingham, A., Collins, P.L., The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl. Acad. Sci. U. S. A. 96:20 (1999), 11259–11264.
5. Bitko, V., Barik, S., Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol., 1(1), 2001, 34.
6. Bobbin, M.L., Burnett, J.C., Rossi, J.J., RNA interference approaches for treatment of HIV-1 infection. Genome Med., 7(1), 2015, 50.
7. Brown, M., Wittwer, C., Flow cytometry: principles and clinical applications in hematology. Clin. Chem. 46:8 (2000), 1221–1229.
8. Chen, Y., Cheng, G., Mahato, R.I., RNAi for treating hepatitis B viral infection. Pharm. Res. 25:1 (2008), 72–86.
9. Cohen, C., Walaza, S., Moyes, J., Groome, M., Tempia, S., Pretorius, M., Hellferscee, O., Dawood, H., Haffejee, S., Variava, E., Epidemiology of severe acute respiratory illness (SARI) among adults and children aged ≥ 5 years in a high HIV-Prevalence setting, 2009–2012. PLoS One, 10(2), 2015, e0117716.
10. Collins, P.L., Dickens, L.E., Buckler-White, A., Olmsted, R.A., Spriggs, M.K., Camargo, E., Coelingh, K.V., Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc. Natl. Acad. Sci. U. S. A. 83:13 (1986), 4594–4598.
11. Collins, P.L., Hill, M.G., Johnson, P.R., The two open reading frames of the 22 K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. J. Gen. Virol. 71:12 (1990), 3015–3020.
12. DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., Cehelsky, J., Nochur, S., Walsh, E., Meyers, R., Gollob, J., Vaishnaw, A., A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. U. S. A. 107:19 (2010), 8800–8805.
13. Dykxhoorn, D.M., Lieberman, J., The silent revolution RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 56 (2005), 401–423.
14. Glezen, W.P., Taber, L.H., Frank, A.L., Kasel, J.A., Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:6 (1986), 543–546.
15. Hall, C. Breese, The burgeoning burden of respiratory syncytial virus among children. Infect. Disord. Drug Targets 12:2 (2012), 92–97.
16. Kain, S.R., Adams, M., Kondepudi, A., Yang, T.T., Ward, W.W., Kitts, P., Green fluorescent protein as a reporter of gene expression and protein localization. Biotechniques 19:4 (1995), 650–655.
17. Khanna, M., Saxena, L., Rajput, R., Kumar, B., Prasad, R., Gene silencing: a therapeutic approach to combat influenza virus infections. Future Microbiol. 10:1 (2015), 131–140.
18. Kolokoltsov, A.A., Saeed, M.F., Freiberg, A.N., Holbrook, M.R., Davey, R.A., Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Dev. Res. 70:4 (2009), 255–265.
19. Kong, X., Zhang, W., Lockey, R.F., Auais, A., Piedimonte, G., Mohapatra, S.S., Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet. Vaccines Ther. 5:4 (2007), 593–598.
20. Li, Y., To, J., Verdià-Baguena, C., Dossena, S., Surya, W., Huang, M., Paulmichl, M., Liu, D.X., Aguilella, V.M., Torres, J., Inhibition of the human respiratory syncytial virus small hydrophobic protein and structural variations in a bicelle environment. J. Virol. 88:20 (2014), 11899–11914.
21. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S.Y., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2013), 2095–2128.
22. Mao, S., Sun, W., Kissel, T., Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 62:1 (2010), 12–27.
23. Meng, J., Stobart, C.C., Hotard, A.L., Moore, M.L., An overview of respiratory syncytial virus. PLoS Pathog., 10(4), 2014, e1004016.
24. Modjarrad, K., Giersing, B., Kaslow, D.C., Smith, P.G., Moorthy, V.S. 2015. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23–24 March 2015. Vaccine.
25. Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., O'Brien, K.L., Roca, A., Wright, P.F., Bruce, N., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:9725 (2010), 1545–1555, 10.1016/S0140-6736(10)60206-1.
26. Nolan, T., Borja-Tabora, C., Lopez, P., Weckx, L., Ulloa-Gutierrez, R., Lazcano-Ponce, E., Kerdpanich, A., Weber, M.A.R., de Los Santos, A.M., Tinoco, J.-C., Prevalence and incidence of respiratory syncytial virus and other respiratory viral infections in children 6 months to 10 years of age with influenza-like illness enrolled in a randomized trial. Clin. Infect. Dis., 2015, civ065.
27. Oliveira, T.F., Freitas, G.R., Ribeiro, L.Z., Yokosawa, J., Siqueira, M.M., Portes, S.A., Silveira, H.L., Calegari, T., Costa, L.F., Mantese, O.C., Queiróz, D.A., Prevalence and clinical aspects of respiratory syncytial virus A and B groups in children seen at Hospital de Clínicas of Uberlândia, MG, Brazil. Mem. Inst. Oswaldo Cruz 103 (2008), 417–422, 10.1590/S0074-02762008000500002.
28. Pascolo, S., Messenger RNA-based vaccines. Expert Opin. Biol. Ther. 4:8 (2004), 1285–1294.
29. Rácz, Z., Hamar, P., Can siRNA technology provide the tools for gene therapy of the future?. Curr. Med. Chem. 13:19 (2006), 2299–2307.
30. Radhakrishnan, S.K., Layden, T.J., Gartel, A.L., RNA interference as a new strategy against viral hepatitis. Virology 323:2 (2004), 173–181.
31. Rothe, D., Wade, E.J., Kurreck, J., Design of small interfering RNAs for antiviral applications. Antiviral RNAi, 2011, Springer, 267–292.
32. Ruuskanen, O., Ogra, P.L., Respiratory syncytial virus. Curr. Probl. Pediatr. 23:2 (1993), 50–79.
33. Silva, J.M., Hammond, S.M., Hannon, G.J., RNA interference: a promising approach to antiviral therapy?. Trends Mol. Med. 8:11 (2002), 505–508.
34. Simões, E.A., DeVincenzo, J.P., Boeckh, M., Bont, L., Crowe, J.E., Griffiths, P., Hayden, F.G., Hodinka, R.L., Smyth, R.L., Spencer, K., Challenges and opportunities in developing respiratory syncytial virus therapeutics. J. Infect. Dis. 211:1 (2015), S1–S20.
35. Ter Brake, O., ‘t Hooft, K., Liu, Y.P., Centlivre, M., von Eije, K.J., Berkhout, B., Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther. 16 (2008), 557–564.
36. Turner, T.L., Kopp, B.T., Paul, G., Landgrave, L.C., Hayes, D., Thompson, R., Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 6 (2014), 217–225, 10.2147/CEOR.S60710.